Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

NCT00793013 | Withdrawn Phase 2

• 1 other identifier: 123456789
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Traditional modes of ventilation have failed to improve patient survival. Subsequent observations that elevated airway pressures observed in traditional forms of ventilation resulted in barotrauma and extension of ALI lead to the evolution of low volume cycled ventilation as a potentially better ventilatory modality for ARDS. Recent multicenter trials by the NIH-ARDS network have confirmed that low volume ventilation increases the number of ventilatory free days and improves overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.

Conditions

Acute Lung Injury; Adult Respiratory Distress Syndrome; Kidney Injury

Keywords

Acute Lung Injury; Adult Respiratory Distress Syndrome; Airway Pressure Release Ventilation; Acute Kidney Injury; Pressure Trial

Outcome Measures

Primary Outcomes (1)

• All cause mortality

  28 days or prior to hospital discharge

Secondary Outcomes (6)

• Number of ventilator-free days

  28 days or prior to hospital discarge

• Length of ICU stay and /or Total hospital days

  28 days or prior to hospital discharge

• To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the incidence of of AKI

  28 days or prior to hospital discharge

• To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the NGAL, KIM-1, and IL-18 urine biomarkers for AKI

  28 days or prior to hospital discharge

• To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation in maintaining hourly urine output > 0.5 mls/kg/hr

  28 days or prior to hospital discharge

Study Arms (2)

ARDS Net Low Tidal Volume

EXPERIMENTAL

Device: Volume-Cycled Assist-Control (AC) mode

APRV Ventilation

EXPERIMENTAL

Device: Airway Pressure Release Ventilation (APRV) mode

Interventions

Volume-Cycled Assist-Control (AC) mode DEVICE

1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40% 2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min 3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2 4. Inspiratory to Expiratory ratio set at 1:1 to 1:3 5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased 6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol 7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95% 8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol

Also known as: Controlled Mechanical Ventilation (CMV)

ARDS Net Low Tidal Volume

Airway Pressure Release Ventilation (APRV) mode DEVICE

1. Ventilation uses Drager Model X1 2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels 3. Time periods for the high \& low pressure levels can be set independently 4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume 5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min 6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min 7. If spontaneous breathing is achieved,level of sedation will be decreased 8. If spontaneous respirations are \>20 breaths/min, sedation will be increased 9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased

Also known as: Controlled Mechanical Ventilation (CMV)

APRV Ventilation

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients admitted to the Internal Medicine service at the Baroness Erlanger Hospital of the University of Tennessee College of Medicine with hypoxia (O2 saturation \< 93%) and pulmonary distress, will be screened for study participation.
• Patients displaying all the following clinical criteria: acute onset of respiratory failure; hypoxia defined as a PaO2/FiO2 ratio of \< 300 Torr; pulmonary capillary wedge pressure less or equal than 18 mm Hg, and/or no clinical evidence of left sided heart failure; and chest x-ray with diffuse bilateral pulmonary infiltrates.

You may not qualify if:

• Patients receiving conventional volume ventilation with or without PEEP for \> 6 hours prior to study enrollment
• Patient's family or surrogate unwilling to give informed consent
• Patients requiring sedation or paralysis for effective ventilation
• Patients known pulmonary embolus within 72 hours of study enrollment
• Patients with close head injuries or evidence of increased intracranial pressure
• Patients with burns over 30% of total body surface area
• Pulmonary capillary wedge pressure greater than 18 mm Hg
• CVP \> 15 cm H2O
• Patients with B type Naturetic peptide levels \> 1000
• Patients with prior history of dilated cardiomyopathy with EF \< 25%
• Patients receiving chronic outpatient peritoneal or hemodialysis
• Patients with severe liver disease (as defined by Child-Pugh class C)
• AIDS patients

Sponsors & Collaborators

• University of Tennessee, Chattanooga: lead

Study Sites (1)

James A. Tumlin, MD

Chattanooga, Tennessee, 37403, United States

Location

MeSH Terms

Conditions

Acute Lung Injury; Respiratory Distress Syndrome; Acute Kidney Injury

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

Lung Injury; Lung Diseases; Respiratory Tract Diseases; Respiration Disorders; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Positive-Pressure Respiration; Respiration, Artificial; Airway Management; Therapeutics; Respiratory Therapy

Study Officials

• James A Tumlin, MD

  University of Tennessee

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2008
• First Posted: November 18, 2008
• Study Start: November 2, 2020
• Primary Completion: November 2, 2020
• Study Completion: November 2, 2020
• Last Updated: November 4, 2020

Record last verified: 2020-11

Locations

US (1)